secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001682852-23-000049
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Moderna CCO Arpa Garay departs; CEO & President to oversee commercial org
-------------------------------------------------------------------------

- Arpa Garay no longer serves as Chief Commercial Officer effective Dec 8, 2023.
- Commercial organization will be overseen by CEO Stéphane Bancel and President Stephen Hoge.
- Garay to remain as employee through June 2024 in advisory capacity for transition.
- Severance includes 12 months salary ($850,000), target bonus ($765,000), and COBRA.
- Accelerated vesting of 15% of unvested time-based equity awards, plus 12-month option exercise window.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000049/0001682852-23-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000049/mrna-20231208.htm
  HTML page:      https://secwatch.observer/filing/0001682852-23-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer